We are honored to welcome these distinguished physician scientists to our inaugural SAB! Each is recognized as a leader in the oncology community, and we look forward to benefiting from their deep experience. https://t.co/wtoDguiacC
#clickchemistry#CancerResearch#oncology
It's showtime at #AACR24! 🎉
The Shasqi team is thrilled to present our latest research findings using an MMAE bound activator to activate a Trop2 protodrug at the tumor. Spoiler alert: it results in sustained tumor regression.
Come say hi!
9am-12.30pm today, Monday April 8th.
Can't make it in person? Check out the posters right here:
Poster Board 1: https://t.co/0n4i9Ps7tL
Poster Board 2: https://t.co/RCglML8kXZ
Poster Board 3: https://t.co/d056FTt51D
Poster Board 4: https://t.co/Rx8RydZCT7
Time for a group photo! 📸Between 9am and 12.30pm PST today, you’ll find the Shasqi team presenting 4 posters on our CAPAC technology, so stop by to learn how it clicks!
Poster Section 26, Poster 1-4.
#oncology#research#innovation#AACR24
Double Click to hear from VP of Research Travis Biechele and Scientist Stefanie Wagner as they give you the inside scoop from #AACR24! 👥⬇️
And don’t forget to come find us tomorrow, Wednesday April 10th at 9am to see some new data from our CAPAC platform.
#oncology#research
The @AACR had six women Presidents in its first 90 years. On Monday, Dr. LoRusso will become the seventh woman AACR President in the last 15 years. We are grateful to #AACRWICR for all they do to advance leadership opportunities for #WomenInOncology. #AACR24
We're looking forward to @CarolynBertozzi’s talk on next generation cancer therapies enabled by bioorthogonal chemistry at #AACR24. For the uninitiated, bioorthogonal chemistry is the technology behind Shasqi's tumor targeted drug activation platform. #oncology#nobelprize
Inspiring Science | Fueling Progress | Revolutionizing Care: #AACR24 Program Chairs Keith T. Flaherty, MD, and Christina Curtis, PhD, convene the Opening Plenary Session of the AACR Annual Meeting 2024.
#AACR24 quote of the day: "If the 2010s were the decade of PD-1 inhibitors, then the 2020s are the decade of ADCs."
We agree, Scott Ebbinghaus @Merck. Really enjoyed hearing you speak at the @AACR Oncology Industry Partnering Event yesterday.
#ADC#oncology
I was delighted to join @AACRPres Phil Greenberg, @AACR President-Elect Pat LoRusso, and President-Elect Designate Lillian Siu at the #AACR24 Board of Directors meeting. We thank our officers and board members for all they do to advance the AACR's mission.
We’ll be back at the @AACR meeting this year presenting 5 posters highlighting data on our novel tumor targeted drug activation approach.
Stop by to say hi 👋 and grab a copy of our poster!
#oncology#ADC#AACR24
"Don't sleep on founder-led biotech startups" Thanks @eperlste for the shoutout in Ep90 of @BiotechCH 🙏 We couldn't agree more!
https://t.co/TmdNXK64kH